COMMUNIQUÉS West-GlobeNewswire

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended [...]
PacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Partner
12/02/2026
Integration of HiFi Long-Read Whole-Genome Sequencing Expands the Collective Capabilities of iHope’s Global Rare Disease Network MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading [...]
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
12/02/2026
PYRUKYND ® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre- [...]
Vistin Pharma ASA (VISTN): Key information relating to the proposed cash dividend
12/02/2026
The Board of Directors will propose for the AGM to get a power of attorney to pay-out an ordinary cash dividend of up to NOK 1.50 per share, to be paid partly with NOK 1 in May and up to NOK 0.50 in November, for the [...]
Velocity Clinical Research Appoints UK Medical Director
12/02/2026
DURHAM, N.C. , Feb. 12, 2026 (GLOBE NEWSWIRE) -- Velocity Clinical Research today announces the appointment of Dr. Ronnie Beboso as UK Medical Director, strengthening the organization’s medical leadership as it [...]
Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth
12/02/2026
VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation FORT MILL, S.C., Feb. 12, 2026 (GLOBE [...]
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
12/02/2026
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will [...]
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
12/02/2026
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo [...]
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
12/02/2026
– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE [...]
Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals
12/02/2026
CC Pharma Agreement Bolsters Tilray’s UK Growth, Strengthening Distribution to Pharmacy and Hospital Channels NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray [...]
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 [...]
EDAP Announces Appointment of David Horn to Board of Directors
12/02/2026
EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) (“the Company” or “EDAP”), a global leader in therapeutic ultrasound technology, today [...]
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
12/02/2026
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
12/02/2026
New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has [...]
Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG
12/02/2026
Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG Boston, MA, USA and Oxford, UK – 12 February 2026 , Vitaccess, a leader in generating [...]
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
12/02/2026
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its [...]
Ipsen réalise de solides résultats en 2025, grâce à une performance soutenue de toutes les aires thérapeutiques, et annonce ses objectifs 2026
12/02/2026
Croissance des ventes totales du Groupe en 2025 de 10,9% à taux de change constant 1 (8,1% en données publiées), tirée par la croissance des trois aires thérapeutiques avec une croissance de 4,1% 1 en Oncologie, 102,5% [...]
NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
12/02/2026
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its [...]
Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission
12/02/2026
Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results [...]

Pages